Inhalational high molecular weight heparin for the treatment of Sars-CoV-2

Faculdade de Medicina de Botucatu - UNESP0 个研究点开始时间: 2021年2月10日最近更新: 2023年5月29日

试验速览

暂无简介。

•Sign and agree to the Informed Consent Form; Both sexes, of any ethnic origin, aged between 18 and 90 years; COVID-19 patients diagnosed by RT-PCR (reverse-transcriptase polymerase chain reaction) or with a strong suspicion of COVID-19 by clinical evaluation through compatible clinical and radiological findings;
•4. Time of disease evolution less than 10 days;
•5. Radiological diagnosis of pneumonia grade 2 A, with gas exchange ratio> 200 on blood gas analysis (paO2 / pFiO2), characterizing mild hypoxemia;
•6. Indication of hospital treatment regime, provided that the period of hospitalization before inclusion is not more than 24 hours;
•7. Need for supplemental oxygen therapy (O2) less than 5L / min.

•Do not agree with the terms of the study; Moderate or severe respiratory failure requiring admission to the Intensive Care Unit (ICU) with the need for invasive mechanical ventilation or non-invasive ventilation with positive pressure (NIV); Pregnancy or puerperium; People with hematological diseases, coagulation disorders, use of anticoagulants; previous heparin-induced allergy or thrombocytopenia, thrombocytopenia with a count of less than 50.000 platelets / mm3; No diagnostic confirmation of COVID-19 by RT-PCR within 72 hours of inclusion in the study.

发起方

Faculdade de Medicina de Botucatu - UNESP